- Conditions
- Cardiogenic Shock, Heart Failure
- Interventions
- Pulmonary Artery Catheter
- Device
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 1,066
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Deep Vein Thrombosis
- Interventions
- Comprehensive Duplex Ultrasound (diagnostic study)
- Other
- Lead sponsor
- Intermountain Health Care, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 2
- States / cities
- Murray, Utah • Salt Lake City, Utah
- Conditions
- Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Head and Neck Cancer, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, Pancreatic Cancer, CLL, Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
- Interventions
- CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine, CYT-0851 in combination with rituximab and bendamustine
- Drug
- Lead sponsor
- Cyteir Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 16
- States / cities
- San Francisco, California • Stanford, California • Denver, Colorado + 12 more
- Conditions
- Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension, Interstitial Lung Disease
- Interventions
- ROC-101
- Drug
- Lead sponsor
- AllRock Bio, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Rancho Cordova, California • Aurora, Colorado + 8 more
- Conditions
- Cancer, Cancer Metastatic, Neoplasms, Breast Cancer, Lung Cancer, Thyroid Cancer, Lymphoma, Lymphoma, Non-Hodgkin, Hodgkin Lymphoma, Leukemia, Sarcoma, Skin Cancer, Bone Cancer, Gynecologic Cancer, Pancreas Cancer, Multiple Myeloma, Colorectal Cancer, Gastrointestinal Cancer, Prostate Cancer, Glioblastoma, Brain Cancer, Head and Neck Cancer
- Interventions
- Virtual group based physical activity (BurnAlong) and Social Media Discussion Board
- Behavioral
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years to 39 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Pulmonary; Hypertension, Steatosis, Right Ventricular Failure
- Interventions
- Omega-3 fatty acids
- Dietary Supplement
- Lead sponsor
- Wen-Chih Wu
- Federal
- Eligibility
- 30 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Conditions, Infections, Heart Failure, Renal and Urinary Disorders, Diabetes, Hypertension, Fever, Bronchitis, Asthma, Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Digital Care Solution as supportive personalized care, Traditional Hospital Level Care
- Other
- Lead sponsor
- OSF Healthcare System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9,654 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Peoria, Illinois
- Conditions
- COVID-19, Vaccine Adverse Reaction, Vaccine Reaction, Vaccine or Biological Substance, Unspecified Causing Adverse Effects in Therapeutic Use, Corona Virus Infection, Blood Clot, Thrombocytopenia, Neuritis, Vasculitis, Influenza, Guillain-Barré, GWAS, Genetic Sequencing
- Interventions
- vaccinated
- Biological
- Lead sponsor
- Neuroganics LLC
- Industry
- Eligibility
- 5 Years to 99 Years
- Enrollment
- 100,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Northglenn, Colorado
- Conditions
- Pulmonary Embolism, Embolism, Embolism and Thrombosis, Vascular Diseases, Cardiovascular Diseases, Lung Diseases, Respiratory Tract Diseases
- Interventions
- Thrombectomy
- Device
- Lead sponsor
- Inquis Medical, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 26
- States / cities
- Scottsdale, Arizona • Fairfield, California • Long Beach, California + 23 more
- Conditions
- Infant, Newborn, Respiratory Insufficiency, Pulmonary Hypertension, Respiratory Distress Syndrome, Newborn, Streptococcal Infections
- Interventions
- Inhaled Prostaglandin E1
- Drug
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- Up to 7 Days
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Palo Alto, California • Iowa City, Iowa + 7 more
- Conditions
- Airway Inflammation
- Interventions
- placebo, Montelukast
- Other · Drug
- Lead sponsor
- Marywood University
- Other
- Eligibility
- 18 Years to 30 Years · Male only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Scranton, Pennsylvania
- Conditions
- Prematurity, Bronchopulmonary Dysplasia, Intraventricular Hemorrhage, Periventricular Leukomalacia
- Interventions
- inhaled nitric oxide, oxygen
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 2 Hours to 72 Hours
- Enrollment
- 273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2023
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis
- Interventions
- Rituximab plus cyclophosphamide placebo (rituximab group), Cyclophosphamide plus rituximab placebo (control group), Azathioprine, Methylprednisolone (or other glucocorticoid), Prednisone
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 15 Years and older
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 4 more
- Conditions
- Acute Pulmonary Embolism
- Interventions
- ThromboView
- Other
- Lead sponsor
- Agen Biomedical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 4
- States / cities
- Sacramento, California • San Diego, California • Detroit, Michigan + 1 more
- Conditions
- Pulmonary Hypertension
- Interventions
- Not listed
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- COVID-19
- Interventions
- Crizanlizumab, 0.9% saline
- Drug · Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Deep Vein Thrombosis, Pulmonary Embolism
- Interventions
- Enoxaparin, Apixaban, Enoxaparin-matching placebo, Apixaban-matching placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,407 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 12 more
- Conditions
- Pulmonary Vein Stenosis
- Interventions
- LA transplant
- Procedure
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- Up to 17 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hypertension, Pulmonary
- Interventions
- Not listed
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Manhasset, New York
- Conditions
- Pulmonary Hypertension
- Interventions
- UT-15C 1 mg, UT-15C 0.25 mg, UT-15C 5 mg, Placebo
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 19 more
- Conditions
- Ischemia-Reperfusion Injury, Lung Transplantation
- Interventions
- Repertaxin, Placebo
- Drug · Other
- Lead sponsor
- Dompé Farmaceutici S.p.A
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Denver, Colorado • St Louis, Missouri + 2 more
- Conditions
- Rheumatic Disease
- Interventions
- Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide, Azathioprine, Mycophenolate, Cyclosporine, Tacrolimus, Etanercept, Adalimumab, Golimumab, Certolizumab, Infliximab, Rituximab, Belimumab, Tocilizumab, Anakinra, Canakinumab, Abatacept, Secukinumab, Ixekizumab, Bimekizumab, Ustekinumab, Guselkumab, Risankizumab, Tofacitinib, Upadacitinib
- Drug · Biological
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Bronchopulmonary Dysplasia (BPD), Hypertension, Pulmonary
- Interventions
- Not listed
- Lead sponsor
- Stanford University
- Other
- Eligibility
- Up to 30 Weeks
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2019
- U.S. locations
- 2
- States / cities
- Mountain View, California • Palo Alto, California
- Conditions
- Colon Cancer, Lung Cancer, Atrial Fibrillation, Diabetes Type 2, Obesity, Breast Cancer, Graves Disease, Osteoarthritis, Celiac Disease, Myocardial Infarction, Prostate Cancer
- Interventions
- SNP analysis
- Genetic
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota